couter

PTHSPelthos Therapeutics Inc.

Health CareBiotechnology

The Read

Pelthos Therapeutics' stock surged about 26-29% on Q1 2026 earnings as strong commercial execution and a 17% revenue rise for ZELSUVMI, driven by 25% more dispensed units, reassured investors on growth and cash runway.
Oct 15, 2026 — Cash Runway Depletion & Equity Financing Risk
Chart by TradingView

The schedule

  • Thu15Oct

    Critical window for capital structure resolution as operating cash burn depletes remaining runway, risking a drop to $18.00 or a non-dilutive relief rally to $37.00.

  • Thu11Feb

    Q3 results will detail post-financing capitalization and market share capture, steering shares toward $13.00 or exposing a $13.00 floor.

  • Thu25Feb

    Full-year 2026 results and initial 2027 guidance on the path to cash-flow breakeven, framing a $20.00 target against an $8.00 downside.

  • Thu13May

    Q1 2027 update tracking seasonal dermatology trends and pipeline execution, charting a path to $26.00 or $14.00.

  • Thu13May

Past

  • Thu13Aug

    Pelthos reports Q2 results, with a focus on ZELSUVMI prescription volume tracking against a $34.00 upside versus a $22.00 downside.

  • Fri24Jul

    Actual outcome: Bull

    Pelthos Therapeutics announced the scheduling of its 2026 Annual Meeting of Stockholders, but did not release the anticipated clinical pipeline or data updates. Despite the lack of new clinical catalysts, the stock rose 6.4% over the period, reflecting positive market sentiment.

    Company’s fall 2026 R&D and clinical pipeline update, potentially including new data or development timelines beyond ZELSUVMI. Convincing efficacy and expansion opportunities could re-rate the story toward $38.00, while underwhelming data or delays could drag the stock back toward $38.00.

  • Thu14May

    Actual outcome: Bull · $29.00 at outcome

    Pelthos Therapeutics reported a Q1 loss of $3.09 per share, meeting or beating estimates, alongside strong commercial execution. Net product revenue for its lead product, ZELSUVMI, grew 17% quarter-over-quarter to $10.7 million, driven by a 25% increase in dispensed units. This continued prescription growth and solid revenue traction reassured investors about the company's cash runway, driving the stock past the $27.00 bull target.

    First look at 2026 operating spend and cash runway, with Q1 2026 earnings on 2026-05-15 expected to update revenue traction from initial licensing or collaboration deals and clarify how long Pelthos Therapeutics Inc. can fund its pipeline at a $23.00 share price.